<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="204519">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000458</url>
  </required_header>
  <id_info>
    <org_study_id>NIAAAMOA10476</org_study_id>
    <nct_id>NCT00000458</nct_id>
  </id_info>
  <brief_title>Sertraline and Cognitive Therapy in Depressed Alcoholics</brief_title>
  <official_title>Sertraline and Cognitive Therapy in Depressed Alcoholics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess whether individuals treated with sertraline (Zoloft) and cognitive
      behavior therapy will experience improvement with their depression and consume less alcohol
      than individuals treated with a placebo and cognitive behavior therapy. This is a 12-week,
      random assignment, placebo-controlled, double-blind study with followup assessments 1 and 3
      months after treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <completion_date>January 2002</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment</study_design>
  <enrollment>100</enrollment>
  <condition>Alcoholism</condition>
  <condition>Depression</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sertraline (Zoloft)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>cognitive behavior therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meets criteria for major depressive episode.

          -  Meets criteria for alcohol abuse or dependence thirty days prior to entering the
             study.

          -  Has had no more than one previous inpatient medical detoxification.

          -  Able to maintain sobriety for ten days.

          -  Able to read and understand questionnaires and informed consent.

          -  Lives within 50 miles of the study site, has a stable living situation, and a
             reliable source of collateral reporting.

        Exclusion Criteria:

          -  Meets criteria for any other psychoactive substance dependence other than nicotine.

          -  Any psychoactive substance abuse (other than nicotine or marijuana) within 30 days
             before beginning of study.

          -  Meets criteria for other psychiatric disorders including: panic disorder,
             obsessive-compulsive disorder, bipolar affective disorder, cyclothymia,
             schizophrenia, any organic mental disorder, eating disorder, dissociative disorder,
             or post-traumatic stress disorder.

          -  Has evidence of treatment resistant depression defined as more than one previous
             treatment episode for depression, which can include hospitalization and/or one course
             of antidepressant medication.

          -  Patients may not have been prescribed a specific serotonergic medication within the
             month prior to study and may not have taken any antidepressant or antipsychotic
             within the two weeks prior to study.

          -  Current use of disulfiram (Antabuse) or anti-seizure medications.

          -  Clinically significant medical problems: cardiovascular, renal, gastrointestinal, or
             endocrine problems that would limit participation or limit medication ingestion.

          -  Hepatocellular disease.

          -  Females who are pregnant, nursing, or not using a reliable form of birth control.

          -  Current charges pending for violent crime (excluding DUI related offenses).

          -  Previous adverse experience with a serotonin reuptake inhibitor.

          -  Current homicidal or suicidal ideation.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2002</verification_date>
  <lastchanged_date>June 23, 2005</lastchanged_date>
  <firstreceived_date>November 2, 1999</firstreceived_date>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sertraline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
